Tenderwize
Retour à la recherche

Testosterone 1000 mg Injection Solution Discount Agreement

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jul 31, 2027 · 337 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Testosteron (ATC-Code nach WHO: G03BA03)

60/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

60 / 100

Complexité

25 / 100

Facteurs de risque

Purchase volumes are unknown and depend on prescribing and dispensing behavior. No minimum quantities guaranteed.

Buyer can terminate the open-house model early if exclusive agreements are concluded, typically 8-12 months after tende...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Provide Testosterone 1000 mg injection solution under a non-exclusive discount agreement with AOK PLUS.
  • No exclusivity; multiple suppliers may participate.
Afficher le résumé complet

This is a non-exclusive drug discount agreement (Rabattvereinbarung) under German SGB V for Testosterone (ATC G03BA03, 1000 mg injection solution) using an open-house model. Any qualified pharmaceutical entrepreneur can join by signing the agreement without negotiations. No guaranteed purchase volumes, no exclusivity. Agreement ends 31.07.2027. First submission deadline for 01.08.2025 start is 23.06.2025. Electronic submission via DTVP portal. No estimated value or award criteria specified.

Risques

Purchase volumes are unknown and depend on prescribing and dispensing behavior. No minimum quantities guaranteed.

Buyer can terminate the open-house model early if exclusive agreements are concluded, typically 8-12 months after tende...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as per §4 Abs.18 AMG for the offered product.
  • Maintain absolute confidentiality of the discount agreement content and discount amount.

Administrative

  • Submit signed discount agreement and required declarations via DTVP portal.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Testosterone 1000 mg Injection Solution Discount Agreement

Non-exclusive discount agreement for Testosterone 1000 mg injection solution under open-house model. Open to all qualified pharmaceutical entrepreneurs. No guaranteed minimum quantities.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Jun 2025 - Jul 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Jul 31, 2027

Détails de la procédure

Date de publication
29 May 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
349760-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30